NEW RAY MEDIC (06108) has reported its interim results for the six months ended June 30, 2026, with revenue reaching HK$113 million, a substantial increase of 153.7% year-on-year. The net loss attributable to shareholders narrowed to HK$3.565 million, representing a reduction of 52.2% compared to the same period last year, with basic loss per share of 1.78 HK cents.

The company attributed the significant revenue growth to increased sales volumes of its pharmaceutical and related products. During the first half of 2026, the group experienced expansion in trading activities and business operations, primarily driven by higher sales of pharmaceutical chemical reagents and increased drug product volumes following the launch of injection drug products in 2025.

Despite the substantial revenue increase during the period, the group recorded a net loss of approximately HK$3.565 million. The reduction in net loss was mainly attributable to the increase in pharmaceutical chemical reagent products and the higher drug sales volume resulting from the 2025 launch of injection drug products.